Bladerunner,
Originally, there were four, phase 2 trials: endometrial, nsclc, breast and prostate. Last summer MRK decided not to pursure ridaforolimus in combination with Herceptin (the results were so/so and from a corporate standpoint it just didn't make a lot of economic sense). Considering how well ridaforolimus and Dalotuzumab (Merck's IGFR-1 inhibitor) performed in luminal B breast cancer, I think MRK made the smart choice in pursuing the combination therapy in breast cancer. I'd look for a follow-on Phase 2 rida+dalo trial to be announced next.
As far as the single-agent trials go, I think the endometrial trial is farthest along so hopefully MRK will provide additional data at some point this summer.
